Brand Name

Omlonti

Generic Name
Omidenepag
View Brand Information
FDA approval date: September 23, 2022
Classification: Prostaglandin E2 Receptor Agonist
Form: Solution

What is Omlonti (Omidenepag)?

Omlonti

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database.
Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database.
Journal: Frontiers in medicine
Published: December 02, 2025
Five-Year Outcomes of Omidenepag Isopropyl Monotherapy for Untreated Primary Open-Angle Glaucoma.
Five-Year Outcomes of Omidenepag Isopropyl Monotherapy for Untreated Primary Open-Angle Glaucoma.
Journal: Cureus
Published: November 28, 2025
Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study.
Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study.
Journal: Veterinary ophthalmology
Published: September 27, 2025
View All Latest Advances